Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BioXcel TherapeuticsBTAIQ -34.14% 3-Year EBITDA Growth Rate is 63.70% as of Jun. 2026. The stock has 2 warning signs investors should review. Among 807 Drug Manufacturers companies, BioXcel Therapeutics ranks better than 91.82% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 63.70% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 38.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 10 years, the highest 3-Year average EBITDA Per Share Growth Rate of BioXcel Therapeutics was 63.70% per year. The lowest was -145.80% per year. And the median was -40.70% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
BioXcel Therapeutics 3-Year EBITDA Growth Rate Related Terms
BTAIQ vs YCBD, APUS, LVRLF: 3-Year EBITDA Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, BioXcel Therapeutics's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioXcel Therapeutics 3-Year EBITDA Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, BioXcel Therapeutics's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where BioXcel Therapeutics's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 63.70% mean?
BioXcel Therapeutics (BTAIQ) has a 3-Year EBITDA Growth Rate of 63.70% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for BioXcel Therapeutics and its competitors. According to the industry distribution chart, BioXcel Therapeutics ranks #66 out of 807 companies in the Drug Manufacturers industry, placing it in the top 8.2%.
Is BioXcel Therapeutics' 3-Year EBITDA Growth Rate too high?
BioXcel Therapeutics' current 3-Year EBITDA Growth Rate is 63.70%. The Drug Manufacturers industry median 3-Year EBITDA Growth Rate is 8.90. BioXcel Therapeutics' value of 63.70% is 615.7% above this industry median. Based on the distribution chart, BioXcel Therapeutics ranks #66 out of 807 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers.
How does BioXcel Therapeutics' 3-Year EBITDA Growth Rate compare to YCBD and APUS?
According to the Drug Manufacturers industry distribution chart, BioXcel Therapeutics ranks #66 out of 807 companies for 3-Year EBITDA Growth Rate. This places BioXcel Therapeutics in the top 8% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 8.90. BioXcel Therapeutics' value of 63.70% is 615.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Drug Manufacturers company?
The median 3-Year EBITDA Growth Rate among Drug Manufacturers companies is 8.90, based on 807 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioXcel Therapeutics's current 3-Year EBITDA Growth Rate of 63.70% is 615.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for BioXcel Therapeutics and its competitors. For the Drug Manufacturers industry, the median 3-Year EBITDA Growth Rate is 8.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioXcel Therapeutics's current 3-Year EBITDA Growth Rate is 63.70%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioXcel Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, BioXcel Therapeutics (BTAIQ) is currently considered Possible Value Trap. The stock's GF Value™ is $0.53, compared to a current price of $0.04 — trading 91.9% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 63.70% and 615.7% above the Drug Manufacturers industry median of 8.90. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For BioXcel Therapeutics (BTAIQ), the current 3-Year EBITDA Growth Rate is 63.70% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are-BXCL501, being evaluated as a potential treatment for agitation associated with multiple neurological disorders and BXCL701, an investigational oral innate immune activator for the treatment of aggressive forms of prostate cancer and other solid and liquid tumors. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BTAIQ has been successfully added to your 
